HEADER TRANSFERASE 07-NOV-22 8HE8 TITLE HUMAN ADP-RIBOSYLTRANSFERASE 2 (PARP2) CATALYTIC DOMAIN BOUND TO A TITLE 2 QUINAZOLINE-2,4(1H,3H)-DIONE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: POLY [ADP-RIBOSE] POLYMERASE 2; COMPND 3 CHAIN: A, B, C; COMPND 4 SYNONYM: PARP-2,HPARP-2,ADP-RIBOSYLTRANSFERASE DIPHTHERIA TOXIN-LIKE COMPND 5 2,ARTD2,DNA ADP-RIBOSYLTRANSFERASE PARP2,NAD(+) ADP- COMPND 6 RIBOSYLTRANSFERASE 2,ADPRT-2,POLY[ADP-RIBOSE] SYNTHASE 2,PADPRT-2, COMPND 7 PROTEIN POLY-ADP-RIBOSYLTRANSFERASE PARP2; COMPND 8 EC: 2.4.2.30,2.4.2.-; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PARP2, ADPRT2, ADPRTL2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008 KEYWDS PARP-2, DNA ADP-RIBOSYLTRANSFERASE, INHIBITOR, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR X.Y.WANG,B.L.XU,J.ZHOU REVDAT 1 08-NOV-23 8HE8 0 JRNL AUTH J.ZHOU,T.DU,X.WANG,H.YAO,J.DENG,Y.LI,X.CHEN,L.SHENG,M.JI, JRNL AUTH 2 B.XU JRNL TITL DISCOVERY OF QUINAZOLINE-2,4(1 H ,3 H )-DIONE DERIVATIVES JRNL TITL 2 CONTAINING A PIPERIZINONE MOIETY AS POTENT PARP-1/2 JRNL TITL 3 INHIBITORS─DESIGN, SYNTHESIS, IN VIVO ANTITUMOR JRNL TITL 4 ACTIVITY, AND X-RAY CRYSTAL STRUCTURE ANALYSIS. JRNL REF J.MED.CHEM. V. 66 14095 2023 JRNL REFN ISSN 0022-2623 JRNL PMID 37843892 JRNL DOI 10.1021/ACS.JMEDCHEM.3C01152 REMARK 2 REMARK 2 RESOLUTION. 3.05 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.20.1_4487 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : GEOSTD + MONOMER LIBRARY + CDL V1.2 REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.05 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 41.09 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.370 REMARK 3 COMPLETENESS FOR RANGE (%) : 89.7 REMARK 3 NUMBER OF REFLECTIONS : 19415 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.210 REMARK 3 R VALUE (WORKING SET) : 0.207 REMARK 3 FREE R VALUE : 0.256 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.760 REMARK 3 FREE R VALUE TEST SET COUNT : 924 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 41.0900 - 5.8300 0.86 2581 123 0.1856 0.2405 REMARK 3 2 5.8300 - 4.6300 0.88 2588 136 0.1979 0.2351 REMARK 3 3 4.6300 - 4.0400 0.89 2639 131 0.1950 0.2325 REMARK 3 4 4.0400 - 3.6700 0.90 2627 152 0.2075 0.2662 REMARK 3 5 3.6700 - 3.4100 0.91 2679 102 0.2221 0.2679 REMARK 3 6 3.4100 - 3.2100 0.92 2691 137 0.2418 0.3038 REMARK 3 7 3.2100 - 3.0500 0.92 2686 143 0.2556 0.2995 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.10 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.328 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 25.785 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 56.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 55.66 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 8639 REMARK 3 ANGLE : 0.673 11663 REMARK 3 CHIRALITY : 0.039 1259 REMARK 3 PLANARITY : 0.005 1498 REMARK 3 DIHEDRAL : 11.231 1177 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 8HE8 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBC ON 14-NOV-22. REMARK 100 THE DEPOSITION ID IS D_1300033412. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 14-DEC-21 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRF REMARK 200 BEAMLINE : BL02U1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97918 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 16M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19445 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.050 REMARK 200 RESOLUTION RANGE LOW (A) : 48.260 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 90.0 REMARK 200 DATA REDUNDANCY : 4.700 REMARK 200 R MERGE (I) : 0.14600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 10.1800 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.05 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.16 REMARK 200 COMPLETENESS FOR SHELL (%) : 92.0 REMARK 200 DATA REDUNDANCY IN SHELL : 4.70 REMARK 200 R MERGE FOR SHELL (I) : 0.58860 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.460 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 4TVJ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.72 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.40 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 25% PEG-3350, 0.1 M TRIS-HCL PH 8.3 REMARK 280 -8.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 51.68100 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLN B 581 REMARK 465 LEU C 580 REMARK 465 GLN C 581 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 OE1 GLN A 384 OH TYR B 377 1655 2.14 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 233 -121.30 -127.79 REMARK 500 ASN A 261 96.06 -68.94 REMARK 500 LYS A 269 55.99 -95.49 REMARK 500 HIS A 294 -125.06 -74.75 REMARK 500 SER A 349 -136.74 -77.96 REMARK 500 LEU A 354 66.20 -107.37 REMARK 500 GLU A 355 118.58 176.00 REMARK 500 CYS A 367 114.86 -160.22 REMARK 500 HIS A 394 63.97 -105.95 REMARK 500 PHE A 457 20.09 -143.81 REMARK 500 ASN A 481 31.13 -98.97 REMARK 500 LEU A 538 -177.89 -66.52 REMARK 500 ALA A 541 139.87 85.47 REMARK 500 LEU A 547 -101.57 -115.88 REMARK 500 ASN A 548 76.79 46.80 REMARK 500 PRO A 549 97.87 -51.81 REMARK 500 ASP A 550 148.53 -170.66 REMARK 500 ARG A 570 -38.82 -134.92 REMARK 500 ASN B 247 96.62 -66.62 REMARK 500 ARG B 322 28.64 -142.38 REMARK 500 LYS B 348 44.62 -86.62 REMARK 500 GLU B 350 -156.91 -121.03 REMARK 500 GLN B 352 -70.33 -69.60 REMARK 500 LEU B 354 -39.28 177.08 REMARK 500 GLU B 375 52.68 -92.19 REMARK 500 LEU B 479 -71.06 -75.43 REMARK 500 HIS B 527 30.08 -89.34 REMARK 500 PRO B 537 79.13 -63.78 REMARK 500 ARG B 570 -52.38 -135.04 REMARK 500 SER C 232 70.21 62.44 REMARK 500 LYS C 243 6.53 -67.75 REMARK 500 MET C 258 23.90 -76.54 REMARK 500 LYS C 263 -70.66 -76.37 REMARK 500 ARG C 290 37.04 -84.39 REMARK 500 ALA C 291 -4.06 -159.50 REMARK 500 HIS C 294 60.12 -106.25 REMARK 500 ASP C 312 83.80 -150.06 REMARK 500 ARG C 351 -148.22 -115.46 REMARK 500 GLN C 352 -159.63 -85.76 REMARK 500 LEU C 354 -75.44 -52.13 REMARK 500 THR C 393 2.38 -66.06 REMARK 500 GLU C 408 85.03 -152.34 REMARK 500 LEU C 479 -70.96 -61.47 REMARK 500 GLU C 500 -140.78 -85.91 REMARK 500 ALA C 501 91.39 -161.30 REMARK 500 GLN C 510 25.23 42.38 REMARK 500 LYS C 512 -170.81 -68.71 REMARK 500 SER C 542 -158.08 -99.95 REMARK 500 ASN C 548 85.34 -18.45 REMARK 500 PRO C 549 -71.37 -100.87 REMARK 500 REMARK 500 REMARK: NULL DBREF 8HE8 A 231 581 UNP Q9UGN5 PARP2_HUMAN 231 581 DBREF 8HE8 B 231 581 UNP Q9UGN5 PARP2_HUMAN 231 581 DBREF 8HE8 C 231 581 UNP Q9UGN5 PARP2_HUMAN 231 581 SEQADV 8HE8 SER A 349 UNP Q9UGN5 THR 349 ENGINEERED MUTATION SEQADV 8HE8 ARG A 351 UNP Q9UGN5 LEU 351 ENGINEERED MUTATION SEQADV 8HE8 GLY A 353 UNP Q9UGN5 SER 353 ENGINEERED MUTATION SEQADV 8HE8 LEU A 354 UNP Q9UGN5 PRO 354 ENGINEERED MUTATION SEQADV 8HE8 SER B 349 UNP Q9UGN5 THR 349 ENGINEERED MUTATION SEQADV 8HE8 ARG B 351 UNP Q9UGN5 LEU 351 ENGINEERED MUTATION SEQADV 8HE8 GLY B 353 UNP Q9UGN5 SER 353 ENGINEERED MUTATION SEQADV 8HE8 LEU B 354 UNP Q9UGN5 PRO 354 ENGINEERED MUTATION SEQADV 8HE8 SER C 349 UNP Q9UGN5 THR 349 ENGINEERED MUTATION SEQADV 8HE8 ARG C 351 UNP Q9UGN5 LEU 351 ENGINEERED MUTATION SEQADV 8HE8 GLY C 353 UNP Q9UGN5 SER 353 ENGINEERED MUTATION SEQADV 8HE8 LEU C 354 UNP Q9UGN5 PRO 354 ENGINEERED MUTATION SEQRES 1 A 351 GLU SER GLN LEU ASP LEU ARG VAL GLN GLU LEU ILE LYS SEQRES 2 A 351 LEU ILE CYS ASN VAL GLN ALA MET GLU GLU MET MET MET SEQRES 3 A 351 GLU MET LYS TYR ASN THR LYS LYS ALA PRO LEU GLY LYS SEQRES 4 A 351 LEU THR VAL ALA GLN ILE LYS ALA GLY TYR GLN SER LEU SEQRES 5 A 351 LYS LYS ILE GLU ASP CYS ILE ARG ALA GLY GLN HIS GLY SEQRES 6 A 351 ARG ALA LEU MET GLU ALA CYS ASN GLU PHE TYR THR ARG SEQRES 7 A 351 ILE PRO HIS ASP PHE GLY LEU ARG THR PRO PRO LEU ILE SEQRES 8 A 351 ARG THR GLN LYS GLU LEU SER GLU LYS ILE GLN LEU LEU SEQRES 9 A 351 GLU ALA LEU GLY ASP ILE GLU ILE ALA ILE LYS LEU VAL SEQRES 10 A 351 LYS SER GLU ARG GLN GLY LEU GLU HIS PRO LEU ASP GLN SEQRES 11 A 351 HIS TYR ARG ASN LEU HIS CYS ALA LEU ARG PRO LEU ASP SEQRES 12 A 351 HIS GLU SER TYR GLU PHE LYS VAL ILE SER GLN TYR LEU SEQRES 13 A 351 GLN SER THR HIS ALA PRO THR HIS SER ASP TYR THR MET SEQRES 14 A 351 THR LEU LEU ASP LEU PHE GLU VAL GLU LYS ASP GLY GLU SEQRES 15 A 351 LYS GLU ALA PHE ARG GLU ASP LEU HIS ASN ARG MET LEU SEQRES 16 A 351 LEU TRP HIS GLY SER ARG MET SER ASN TRP VAL GLY ILE SEQRES 17 A 351 LEU SER HIS GLY LEU ARG ILE ALA PRO PRO GLU ALA PRO SEQRES 18 A 351 ILE THR GLY TYR MET PHE GLY LYS GLY ILE TYR PHE ALA SEQRES 19 A 351 ASP MET SER SER LYS SER ALA ASN TYR CYS PHE ALA SER SEQRES 20 A 351 ARG LEU LYS ASN THR GLY LEU LEU LEU LEU SER GLU VAL SEQRES 21 A 351 ALA LEU GLY GLN CYS ASN GLU LEU LEU GLU ALA ASN PRO SEQRES 22 A 351 LYS ALA GLU GLY LEU LEU GLN GLY LYS HIS SER THR LYS SEQRES 23 A 351 GLY LEU GLY LYS MET ALA PRO SER SER ALA HIS PHE VAL SEQRES 24 A 351 THR LEU ASN GLY SER THR VAL PRO LEU GLY PRO ALA SER SEQRES 25 A 351 ASP THR GLY ILE LEU ASN PRO ASP GLY TYR THR LEU ASN SEQRES 26 A 351 TYR ASN GLU TYR ILE VAL TYR ASN PRO ASN GLN VAL ARG SEQRES 27 A 351 MET ARG TYR LEU LEU LYS VAL GLN PHE ASN PHE LEU GLN SEQRES 1 B 351 GLU SER GLN LEU ASP LEU ARG VAL GLN GLU LEU ILE LYS SEQRES 2 B 351 LEU ILE CYS ASN VAL GLN ALA MET GLU GLU MET MET MET SEQRES 3 B 351 GLU MET LYS TYR ASN THR LYS LYS ALA PRO LEU GLY LYS SEQRES 4 B 351 LEU THR VAL ALA GLN ILE LYS ALA GLY TYR GLN SER LEU SEQRES 5 B 351 LYS LYS ILE GLU ASP CYS ILE ARG ALA GLY GLN HIS GLY SEQRES 6 B 351 ARG ALA LEU MET GLU ALA CYS ASN GLU PHE TYR THR ARG SEQRES 7 B 351 ILE PRO HIS ASP PHE GLY LEU ARG THR PRO PRO LEU ILE SEQRES 8 B 351 ARG THR GLN LYS GLU LEU SER GLU LYS ILE GLN LEU LEU SEQRES 9 B 351 GLU ALA LEU GLY ASP ILE GLU ILE ALA ILE LYS LEU VAL SEQRES 10 B 351 LYS SER GLU ARG GLN GLY LEU GLU HIS PRO LEU ASP GLN SEQRES 11 B 351 HIS TYR ARG ASN LEU HIS CYS ALA LEU ARG PRO LEU ASP SEQRES 12 B 351 HIS GLU SER TYR GLU PHE LYS VAL ILE SER GLN TYR LEU SEQRES 13 B 351 GLN SER THR HIS ALA PRO THR HIS SER ASP TYR THR MET SEQRES 14 B 351 THR LEU LEU ASP LEU PHE GLU VAL GLU LYS ASP GLY GLU SEQRES 15 B 351 LYS GLU ALA PHE ARG GLU ASP LEU HIS ASN ARG MET LEU SEQRES 16 B 351 LEU TRP HIS GLY SER ARG MET SER ASN TRP VAL GLY ILE SEQRES 17 B 351 LEU SER HIS GLY LEU ARG ILE ALA PRO PRO GLU ALA PRO SEQRES 18 B 351 ILE THR GLY TYR MET PHE GLY LYS GLY ILE TYR PHE ALA SEQRES 19 B 351 ASP MET SER SER LYS SER ALA ASN TYR CYS PHE ALA SER SEQRES 20 B 351 ARG LEU LYS ASN THR GLY LEU LEU LEU LEU SER GLU VAL SEQRES 21 B 351 ALA LEU GLY GLN CYS ASN GLU LEU LEU GLU ALA ASN PRO SEQRES 22 B 351 LYS ALA GLU GLY LEU LEU GLN GLY LYS HIS SER THR LYS SEQRES 23 B 351 GLY LEU GLY LYS MET ALA PRO SER SER ALA HIS PHE VAL SEQRES 24 B 351 THR LEU ASN GLY SER THR VAL PRO LEU GLY PRO ALA SER SEQRES 25 B 351 ASP THR GLY ILE LEU ASN PRO ASP GLY TYR THR LEU ASN SEQRES 26 B 351 TYR ASN GLU TYR ILE VAL TYR ASN PRO ASN GLN VAL ARG SEQRES 27 B 351 MET ARG TYR LEU LEU LYS VAL GLN PHE ASN PHE LEU GLN SEQRES 1 C 351 GLU SER GLN LEU ASP LEU ARG VAL GLN GLU LEU ILE LYS SEQRES 2 C 351 LEU ILE CYS ASN VAL GLN ALA MET GLU GLU MET MET MET SEQRES 3 C 351 GLU MET LYS TYR ASN THR LYS LYS ALA PRO LEU GLY LYS SEQRES 4 C 351 LEU THR VAL ALA GLN ILE LYS ALA GLY TYR GLN SER LEU SEQRES 5 C 351 LYS LYS ILE GLU ASP CYS ILE ARG ALA GLY GLN HIS GLY SEQRES 6 C 351 ARG ALA LEU MET GLU ALA CYS ASN GLU PHE TYR THR ARG SEQRES 7 C 351 ILE PRO HIS ASP PHE GLY LEU ARG THR PRO PRO LEU ILE SEQRES 8 C 351 ARG THR GLN LYS GLU LEU SER GLU LYS ILE GLN LEU LEU SEQRES 9 C 351 GLU ALA LEU GLY ASP ILE GLU ILE ALA ILE LYS LEU VAL SEQRES 10 C 351 LYS SER GLU ARG GLN GLY LEU GLU HIS PRO LEU ASP GLN SEQRES 11 C 351 HIS TYR ARG ASN LEU HIS CYS ALA LEU ARG PRO LEU ASP SEQRES 12 C 351 HIS GLU SER TYR GLU PHE LYS VAL ILE SER GLN TYR LEU SEQRES 13 C 351 GLN SER THR HIS ALA PRO THR HIS SER ASP TYR THR MET SEQRES 14 C 351 THR LEU LEU ASP LEU PHE GLU VAL GLU LYS ASP GLY GLU SEQRES 15 C 351 LYS GLU ALA PHE ARG GLU ASP LEU HIS ASN ARG MET LEU SEQRES 16 C 351 LEU TRP HIS GLY SER ARG MET SER ASN TRP VAL GLY ILE SEQRES 17 C 351 LEU SER HIS GLY LEU ARG ILE ALA PRO PRO GLU ALA PRO SEQRES 18 C 351 ILE THR GLY TYR MET PHE GLY LYS GLY ILE TYR PHE ALA SEQRES 19 C 351 ASP MET SER SER LYS SER ALA ASN TYR CYS PHE ALA SER SEQRES 20 C 351 ARG LEU LYS ASN THR GLY LEU LEU LEU LEU SER GLU VAL SEQRES 21 C 351 ALA LEU GLY GLN CYS ASN GLU LEU LEU GLU ALA ASN PRO SEQRES 22 C 351 LYS ALA GLU GLY LEU LEU GLN GLY LYS HIS SER THR LYS SEQRES 23 C 351 GLY LEU GLY LYS MET ALA PRO SER SER ALA HIS PHE VAL SEQRES 24 C 351 THR LEU ASN GLY SER THR VAL PRO LEU GLY PRO ALA SER SEQRES 25 C 351 ASP THR GLY ILE LEU ASN PRO ASP GLY TYR THR LEU ASN SEQRES 26 C 351 TYR ASN GLU TYR ILE VAL TYR ASN PRO ASN GLN VAL ARG SEQRES 27 C 351 MET ARG TYR LEU LEU LYS VAL GLN PHE ASN PHE LEU GLN HET GOL A 601 6 HET 1WI A 602 34 HET GOL B 601 6 HET 1WI B 602 34 HET 1WI C 601 34 HETNAM GOL GLYCEROL HETNAM 1WI 1-[[4-FLUORANYL-3-(3-OXIDANYLIDENE-4-PENTAN-3-YL- HETNAM 2 1WI PIPERAZIN-1-YL)CARBONYL-PHENYL]METHYL]QUINAZOLINE-2,4- HETNAM 3 1WI DIONE HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 4 GOL 2(C3 H8 O3) FORMUL 5 1WI 3(C25 H27 F N4 O4) FORMUL 9 HOH *19(H2 O) HELIX 1 AA1 ASP A 235 CYS A 246 1 12 HELIX 2 AA2 ASN A 247 MET A 258 1 12 HELIX 3 AA3 PRO A 266 LEU A 270 5 5 HELIX 4 AA4 THR A 271 ALA A 291 1 21 HELIX 5 AA5 HIS A 294 ILE A 309 1 16 HELIX 6 AA6 THR A 323 LYS A 348 1 26 HELIX 7 AA7 HIS A 356 HIS A 366 1 11 HELIX 8 AA8 SER A 376 THR A 389 1 14 HELIX 9 AA9 GLY A 411 PHE A 416 1 6 HELIX 10 AB1 ARG A 431 SER A 433 5 3 HELIX 11 AB2 ASN A 434 GLY A 442 1 9 HELIX 12 AB3 PRO A 451 TYR A 455 5 5 HELIX 13 AB4 MET A 466 TYR A 473 1 8 HELIX 14 AB5 SER A 524 PHE A 528 5 5 HELIX 15 AB6 ASN A 563 ASN A 565 5 3 HELIX 16 AB7 ASP B 235 CYS B 246 1 12 HELIX 17 AB8 ASN B 247 MET B 258 1 12 HELIX 18 AB9 PRO B 266 LEU B 270 5 5 HELIX 19 AC1 THR B 271 ALA B 291 1 21 HELIX 20 AC2 GLY B 295 ILE B 309 1 15 HELIX 21 AC3 THR B 323 LYS B 348 1 26 HELIX 22 AC4 HIS B 356 LEU B 365 1 10 HELIX 23 AC5 SER B 376 THR B 389 1 14 HELIX 24 AC6 GLY B 411 PHE B 416 1 6 HELIX 25 AC7 ARG B 431 SER B 433 5 3 HELIX 26 AC8 ASN B 434 GLY B 442 1 9 HELIX 27 AC9 PRO B 451 TYR B 455 5 5 HELIX 28 AD1 MET B 466 ASN B 472 1 7 HELIX 29 AD2 TYR B 473 PHE B 475 5 3 HELIX 30 AD3 SER B 525 PHE B 528 5 4 HELIX 31 AD4 ASN B 563 ASN B 565 5 3 HELIX 32 AD5 ASP C 235 CYS C 246 1 12 HELIX 33 AD6 ASN C 247 MET C 258 1 12 HELIX 34 AD7 PRO C 266 LEU C 270 5 5 HELIX 35 AD8 THR C 271 ARG C 290 1 20 HELIX 36 AD9 GLY C 295 ILE C 309 1 15 HELIX 37 AE1 LYS C 325 SER C 349 1 25 HELIX 38 AE2 HIS C 356 LEU C 365 1 10 HELIX 39 AE3 SER C 376 SER C 388 1 13 HELIX 40 AE4 GLY C 411 PHE C 416 1 6 HELIX 41 AE5 ASN C 434 GLY C 442 1 9 HELIX 42 AE6 PRO C 451 TYR C 455 5 5 HELIX 43 AE7 MET C 466 ASN C 472 1 7 HELIX 44 AE8 TYR C 473 PHE C 475 5 3 HELIX 45 AE9 LYS C 504 LEU C 509 5 6 HELIX 46 AF1 ASN C 563 ASN C 565 5 3 SHEET 1 AA1 5 CYS A 367 PRO A 371 0 SHEET 2 AA1 5 TYR A 397 LYS A 409 -1 O GLU A 406 N ARG A 370 SHEET 3 AA1 5 VAL A 567 PHE A 579 -1 O ASN A 578 N THR A 398 SHEET 4 AA1 5 THR A 482 ALA A 491 -1 N GLY A 483 O VAL A 575 SHEET 5 AA1 5 ARG A 423 GLY A 429 -1 N HIS A 428 O LEU A 486 SHEET 1 AA2 4 ILE A 461 PHE A 463 0 SHEET 2 AA2 4 GLU A 558 VAL A 561 -1 O TYR A 559 N PHE A 463 SHEET 3 AA2 4 SER A 514 GLY A 517 -1 N GLY A 517 O GLU A 558 SHEET 4 AA2 4 CYS A 495 LEU A 498 1 N ASN A 496 O SER A 514 SHEET 1 AA3 2 MET A 521 ALA A 522 0 SHEET 2 AA3 2 SER A 542 ASP A 543 -1 O SER A 542 N ALA A 522 SHEET 1 AA4 2 VAL A 529 LEU A 531 0 SHEET 2 AA4 2 SER A 534 VAL A 536 -1 O VAL A 536 N VAL A 529 SHEET 1 AA5 5 CYS B 367 PRO B 371 0 SHEET 2 AA5 5 MET B 399 LYS B 409 -1 O GLU B 408 N ALA B 368 SHEET 3 AA5 5 VAL B 567 PHE B 577 -1 O LEU B 572 N PHE B 405 SHEET 4 AA5 5 THR B 482 ALA B 491 -1 N GLU B 489 O ARG B 568 SHEET 5 AA5 5 ARG B 423 GLY B 429 -1 N MET B 424 O VAL B 490 SHEET 1 AA6 4 ILE B 461 PHE B 463 0 SHEET 2 AA6 4 GLU B 558 VAL B 561 -1 O VAL B 561 N ILE B 461 SHEET 3 AA6 4 SER B 514 GLY B 517 -1 N THR B 515 O ILE B 560 SHEET 4 AA6 4 CYS B 495 LEU B 498 1 N LEU B 498 O LYS B 516 SHEET 1 AA7 3 ALA B 541 ASP B 543 0 SHEET 2 AA7 3 GLY B 519 PRO B 523 -1 N ALA B 522 O SER B 542 SHEET 3 AA7 3 LEU B 554 TYR B 556 1 O ASN B 555 N MET B 521 SHEET 1 AA8 2 VAL B 529 LEU B 531 0 SHEET 2 AA8 2 SER B 534 VAL B 536 -1 O VAL B 536 N VAL B 529 SHEET 1 AA9 5 CYS C 367 PRO C 371 0 SHEET 2 AA9 5 THR C 398 LYS C 409 -1 O GLU C 406 N ARG C 370 SHEET 3 AA9 5 VAL C 567 ASN C 578 -1 O ARG C 570 N VAL C 407 SHEET 4 AA9 5 THR C 482 ALA C 491 -1 N GLU C 489 O ARG C 568 SHEET 5 AA9 5 ARG C 423 GLY C 429 -1 N MET C 424 O VAL C 490 SHEET 1 AB1 4 ILE C 461 PHE C 463 0 SHEET 2 AB1 4 GLU C 558 VAL C 561 -1 O VAL C 561 N ILE C 461 SHEET 3 AB1 4 SER C 514 GLY C 517 -1 N GLY C 517 O GLU C 558 SHEET 4 AB1 4 CYS C 495 LEU C 498 1 N LEU C 498 O LYS C 516 SHEET 1 AB2 3 ALA C 541 ASP C 543 0 SHEET 2 AB2 3 GLY C 519 PRO C 523 -1 N ALA C 522 O SER C 542 SHEET 3 AB2 3 LEU C 554 TYR C 556 1 O ASN C 555 N MET C 521 SHEET 1 AB3 2 VAL C 529 THR C 530 0 SHEET 2 AB3 2 THR C 535 VAL C 536 -1 O VAL C 536 N VAL C 529 CRYST1 41.113 103.362 134.925 90.00 92.04 90.00 P 1 21 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.024323 0.000000 0.000866 0.00000 SCALE2 0.000000 0.009675 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007416 0.00000